Healthcare / BiotechnologyNasdaqCM
$8.78
-0.53 (-5.69%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-97.0M · quality 68.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
29/100
D
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$82M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-73.4%
↓Gross Margin
N/A
•Debt/Equity
0.09
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2017–2025 · 8 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.83x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-116.8M · FCF $-97.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | — | — | — | — | $25.0M | — | — | — | — | — |
| Net Income | $-116.8M | $-116.8M | $-117.1M | $-142.7M | $-69.8M | $-62.0M | $-36.7M | $-28.1M | $-9.3M | $-33.8M |
| EBITDA | $-110.4M | $-110.4M | $-110.7M | $-136.5M | $-67.1M | $-59.9M | $-38.0M | $-30.1M | $-13.7M | $-18.9M |
| EPS | -16.95 | -16.95 | -21.28 | -52.96 | -27.20 | -32.00 | — | — | — | — |
| Operating Margin | — | — | — | — | -290.3% | — | — | — | — | — |
| Net Margin | — | — | — | — | -279.3% | — | — | — | — | — |
| Balance Sheet | ||||||||||
| Debt/Equity | 0.09 | 0.09 | 0.09 | 0.12 | 0.07 | — | — | — | — | — |
| Current Ratio | 7.66 | 7.66 | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||
| Free Cash Flow | $-97.0M | $-97.0M | $-93.5M | $-98.2M | $-61.5M | $-64.1M | $-42.5M | $-29.0M | $-19.1M | $-11.0M |
| Returns | ||||||||||
| ROE | -73.4% | -73.4% | -62.8% | -83.8% | -23.9% | -20.5% | -33.4% | 46.6% | 27.7% | 125.3% |
| Valuation | ||||||||||
| P/B | 0.38 | 0.38 | 0.47 | 0.61 | 1.18 | — | — | — | — | — |
| Growth & Yield | ||||||||||
| EPS Growth | 20.3% | 20.3% | 59.8% | -94.7% | — | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-23.6%
Start / end P/E
n/dx → n/dx
EPS bridge
-21.28 → -16.95
Residual
-23.6%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.